Updates are available Correction dated 2025-02-07
Click to view Correction: https://doi.org/10.1007/s13300-025-01697-9
-
Authors
Aranishi, Toshihiko https://orcid.org/0000-0001-8862-9468
Igarashi, Ataru https://orcid.org/0000-0001-6307-6916
Hara, Kazuo
Osumili, Beatrice https://orcid.org/0000-0002-5862-9325
Cai, Zhihong https://orcid.org/0000-0002-3431-197X
Mizogaki, Aska
Sato, Manaka https://orcid.org/0000-0001-7000-4769
Takeuchi, Masakazu https://orcid.org/0000-0003-3176-3118
Minghetti, Alice https://orcid.org/0000-0001-7913-5861
Hunt, Barnaby https://orcid.org/0000-0001-5420-279X
Kadowaki, Takashi
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 20 November 2024
First Online: 21 December 2024
Change Date: 7 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13300-025-01697-9
Declarations
:
: Toshihiko Aranishi, Zhihong Cai, Aska Mizogaki, Manaka Sato, Masakazu Takeuchi and Beatrice Osumili are employees of Eli Lilly and Company. Alice Minghetti and Barnaby Hunt are employees of Ossian Health Economics and Communications, which received consulting fees from Eli Lilly and Company to support preparation for the analysis. Ataru Igarashi received funding from Takeda Pharmaceutical Co. Ltd., MSD, Abbott, AbbVie, Eli Lilly Japan K.K., Gilead Sciences and Terumo and has received consulting fees from Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., CSL Behring Japan Inc., Takeda Pharmaceutical Co., Ltd., Shionogi Co, Ltd., and Eisai Co., Ltd. Kazuo Hara received lecturing fees from Eli Lilly Japan K. K., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co. Ltd., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Novo Nordisk, and Sumitomo Pharma Co. Ltd. Takashi Kadowaki received funding from Nippon Boehringer Ingelheim, Eli Lilly Japan, Novo Nordisk, Kyowa Kirin, MSD Corporation, Daiichi Sankyo, Sanofi, Takeda Pharmaceutical, Astellas Pharma, Ono Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Asahi Mutual Life Insurance Company and serves on the advisory board of Abbott Japan, Medtronic Japan and Novo Nordisk Pharma.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
